RECRUITINGINTERVENTIONAL
Ga-68 FAPI PET Before Immunotherapy
Prognostic Significance of Ga-68 FAPI PET Before Immunotherapy in Pleural Mesothelioma
About This Trial
It is aimed to evaluate FAP expression and its success in predicting treatment response before immunotherapy used in the treatment of malignant mesothelioma with Ga68 FAPI PET/CT imaging, which allows in vivo evaluation of FAP expression, which is thought to be associated with immunosuppression and resistance to immunotherapy.
Who May Be Eligible (Plain English)
Who May Qualify:
- Having a histopathologically confirmed diagnosis of
- Pleural Mesolthelioma
- Patients scheduled for immunotherapy with anti-PDL-1 and/or anti-CTLA-4 antibodies as first or second line therapy
- Patients who gave willing to sign a consent form form to participate in the study
Who Should NOT Join This Trial:
- ECOG\>2
- Patients who did not provide willing to sign a consent form form to participate in the study
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Having a histopathologically confirmed diagnosis of
* Pleural Mesolthelioma
* Patients scheduled for immunotherapy with anti-PDL-1 and/or anti-CTLA-4 antibodies as first or second line therapy
* Patients who gave informed consent form to participate in the study
Exclusion Criteria:
* ECOG\>2
* Patients who did not provide informed consent form to participate in the study
Treatments Being Tested
DIAGNOSTIC_TEST
Ga-68 FAPI PET/CT
imaging of FAP expression of tumor before immunotherapy
Locations (1)
Ankara University School of Medicine
Ankara, Turkey (Türkiye)